کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1394567 | 1501172 | 2011 | 7 صفحه PDF | دانلود رایگان |
The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency. Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamide derivatives were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral analysis, evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT. The results showed that some of the new compounds displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs. However, all newly synthesized derivatives were not active against HIV-2 replication.
Some newly synthesized 1,2,4-triazolacetamide derivatives displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs.Figure optionsDownload as PowerPoint slideHighlights
► A facile synthetic approach towards novel 1,2,4-triazolacetamides was described.
► More than half of the tested compounds were found to be active against HIV-1.
► Some derivatives showed promising activities against several selected resistant strains.
Journal: European Journal of Medicinal Chemistry - Volume 46, Issue 10, October 2011, Pages 5039–5045